Literature DB >> 11564860

Role of p14(ARF) in replicative and induced senescence of human fibroblasts.

W Wei1, R M Hemmer, J M Sedivy.   

Abstract

Following a proliferative phase of variable duration, most normal somatic cells enter a growth arrest state known as replicative senescence. In addition to telomere shortening, a variety of environmental insults and signaling imbalances can elicit phenotypes closely resembling senescence. We used p53(-/-) and p21(-/-) human fibroblast cell strains constructed by gene targeting to investigate the involvement of the Arf-Mdm2-p53-p21 pathway in natural as well as premature senescence states. We propose that in cell types that upregulate p21 during replicative exhaustion, such as normal human fibroblasts, p53, p21, and Rb act sequentially and constitute the major pathway for establishing growth arrest and that the telomere-initiated signal enters this pathway at the level of p53. Our results also revealed a number of significant differences between human and rodent fibroblasts in the regulation of senescence pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564860      PMCID: PMC99853          DOI: 10.1128/MCB.21.20.6748-6757.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  76 in total

1.  Microarray analysis of replicative senescence.

Authors:  D N Shelton; E Chang; P S Whittier; D Choi; W D Funk
Journal:  Curr Biol       Date:  1999-09-09       Impact factor: 10.834

2.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.

Authors:  M K Mateyak; A J Obaya; S Adachi; J M Sedivy
Journal:  Cell Growth Differ       Date:  1997-10

3.  Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts.

Authors:  S J Robles; G R Adami
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

4.  Extension of life-span by introduction of telomerase into normal human cells.

Authors:  A G Bodnar; M Ouellette; M Frolkis; S E Holt; C P Chiu; G B Morin; C B Harley; J W Shay; S Lichtsteiner; W E Wright
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

5.  Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies.

Authors:  V Gire; D Wynford-Thomas
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

6.  Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.

Authors:  C Pantoja; M Serrano
Journal:  Oncogene       Date:  1999-09-02       Impact factor: 9.867

7.  Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

Authors:  T Kamijo; F Zindy; M F Roussel; D E Quelle; J R Downing; R A Ashmun; G Grosveld; C J Sherr
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

Review 8.  Splicing into senescence: the curious case of p16 and p19ARF.

Authors:  D A Haber
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

9.  Telomere shortening and tumor formation by mouse cells lacking telomerase RNA.

Authors:  M A Blasco; H W Lee; M P Hande; E Samper; P M Lansdorp; R A DePinho; C W Greider
Journal:  Cell       Date:  1997-10-03       Impact factor: 41.582

10.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

View more
  69 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 2.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

3.  Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling.

Authors:  A Satyanarayana; R A Greenberg; S Schaetzlein; J Buer; K Masutomi; W C Hahn; S Zimmermann; U Martens; M P Manns; K L Rudolph
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 4.  Epigenetic control of aging.

Authors:  Ursula Muñoz-Najar; John M Sedivy
Journal:  Antioxid Redox Signal       Date:  2010-11-22       Impact factor: 8.401

Review 5.  The essence of senescence.

Authors:  Thomas Kuilman; Chrysiis Michaloglou; Wolter J Mooi; Daniel S Peeper
Journal:  Genes Dev       Date:  2010-11-15       Impact factor: 11.361

6.  Smurf2 up-regulation activates telomere-dependent senescence.

Authors:  Hong Zhang; Stanley N Cohen
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

7.  A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.

Authors:  Alexander D Boiko; Sarah Porteous; Olga V Razorenova; Vadim I Krivokrysenko; Bryan R Williams; Andrei V Gudkov
Journal:  Genes Dev       Date:  2006-01-15       Impact factor: 11.361

8.  ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence.

Authors:  Linan Ha; Takeshi Ichikawa; Miriam Anver; Ross Dickins; Scott Lowe; Norman E Sharpless; Paul Krimpenfort; Ronald A Depinho; Dorothy C Bennett; Elena V Sviderskaya; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

Review 9.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

10.  Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus.

Authors:  Goedele N Maertens; Selma El Messaoudi-Aubert; Tomas Racek; Julie K Stock; James Nicholls; Marc Rodriguez-Niedenführ; Jesus Gil; Gordon Peters
Journal:  PLoS One       Date:  2009-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.